Drugs / Z-1018
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05245838 | Jan → Oct 2022 | herpes zoster | Dynavax Technologies Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06569823 | Jun 2024 → Nov 2027 expected | herpes zoster | Dynavax Technologies Corporation | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Z-1018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05245838 ↗ |
| Modality | Vaccine | “investigational herpes zoster (HZ) vaccine (Z-1018)” NCT05245838 ↗ |
| Route | Intramuscular | “by intramuscular (IM) injection” NCT06569823 ↗ |